Publications by authors named "Mark Demario"

Claim this Profile
P
Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
Jessica S W Borgers, Divya Lenkala, Victoria Kohler, Emily K Jackson, Matthijs D Linssen, Mark DeMario

Nat Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
Jessica S W Borgers, Divya Lenkala, Victoria Kohler, Emily K Jackson, Matthijs D Linssen, Mark DeMario

Nat Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor).
Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, Sabine Wilson, Iakov I Davydov, Mark DeMario

BMC Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
Mark M Awad, Ramaswamy Govindan, Kristen N Balogh, David R Spigel, Edward B Garon, Mark DeMario

Cancer Cell· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
Michael Dickinson, Javier Briones, Alex F Herrera, Eva González-Barca, Nilanjan Ghosh, Mark DeMario

Blood Adv· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Karthik Ramasamy, Ajay Nooka, Hang Quach, Myo Htut, Rakesh Popat, Mark deMario

Blood Cancer J· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.
Gail J Roboz, Pinkal Desai, Sangmin Lee, Ellen K Ritchie, Eric S Winer, Mark DeMario

Leuk Lymphoma· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Geoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, Khanh T Do, Caron A Jacobson, Mark DeMario

Br J Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Patrick A Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, Ramaswamy Govindan, Aung Naing, Mark DeMario

Cell· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
Didier Meulendijks, Ulrik N Lassen, Lillian L Siu, Alwin D R Huitema, Vaios Karanikas, Mark DeMario

Clin Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Ulrik N Lassen, Didier Meulendijks, Lilian L Siu, Vaios Karanikas, Morten Mau-Sorensen, Mark DeMario

Clin Cancer Res· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.
Xuefeng Yin, Leopoldo Luistro, Hua Zhong, Melissa Smith, Tom Nevins, Mark Demario

Clin Cancer Res· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays.
Sabine Lohmann, Andrea Herold, Tobias Bergauer, Anton Belousov, Gisela Betzl, Mark Demario

Methods· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Anthony W Tolcher, Wells A Messersmith, Stanislaw M Mikulski, Kyriakos P Papadopoulos, Eunice L Kwak, Mark Demario

J Clin Oncol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients.
Windy Berkofsky-Fessler, Tri Q Nguyen, Paul Delmar, Juliette Molnos, Charu Kanwal, Mark DeMario

Mol Cancer Ther· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
Apurva A Desai, Federico Innocenti, Linda Janisch, Mark DeMario, Dale Shepard

Cancer Chemother Pharmacol· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
Jakob Dupont, Bryan Bienvenu, Carol Aghajanian, Sandra Pezzulli, Paul Sabbatini, Mark DeMario

J Clin Oncol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
Ramon Salazar, Donald Bissett, Chris Twelves, Lars Breimer, Mark DeMario

Clin Cancer Res· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis